About Topigen Pharmaceuticals
Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.
Missing: Topigen Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Topigen Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Topigen Pharmaceuticals Patents
Topigen Pharmaceuticals has filed 1 patent.
Molecular biology, RNA, DNA, Nucleic acids, Genetics
Molecular biology, RNA, DNA, Nucleic acids, Genetics
Topigen Pharmaceuticals Frequently Asked Questions (FAQ)
When was Topigen Pharmaceuticals founded?
Topigen Pharmaceuticals was founded in 2000.
Where is Topigen Pharmaceuticals's headquarters?
Topigen Pharmaceuticals's headquarters is located at 2901 Rachel, Montreal.
What is Topigen Pharmaceuticals's latest funding round?
Topigen Pharmaceuticals's latest funding round is Other Investors.
Who are the investors of Topigen Pharmaceuticals?
Investors of Topigen Pharmaceuticals include Caisse de depot et placement du Quebec, Desjardins, QHP Capital, MMV Financial, Lothian Partners and 6 more.
Who are Topigen Pharmaceuticals's competitors?
Competitors of Topigen Pharmaceuticals include Aphios, Array Biopharma, Innate Pharma, Ocera Therapeutics, BioMarck Pharmaceuticals and 13 more.
Compare Topigen Pharmaceuticals to Competitors
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
Oraceuticals uses biotechnologies to develop drugs that advance oral treatment and improve oral health. Focuses on producing bioactive molecules that target chronic oral infections and control inflammation.
NovoBiotic has developed a method for growing previously "unculturable" microorganisms in the laboratory. The company is using this proprietary technology as a platform for antibiotic discovery.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.